Sonoma Pharmaceuticals (SNOA) Competitors $2.99 +0.01 (+0.34%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.98 -0.01 (-0.37%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. RLMD, PASG, CASI, CMMB, FNCH, RLYB, SYBX, LPCN, MBRX, and LEXXShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Relmada Therapeutics (RLMD), Passage Bio (PASG), CASI Pharmaceuticals (CASI), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH), Rallybio (RLYB), Synlogic (SYBX), Lipocine (LPCN), Moleculin Biotech (MBRX), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors Relmada Therapeutics Passage Bio CASI Pharmaceuticals Chemomab Therapeutics Finch Therapeutics Group Rallybio Synlogic Lipocine Moleculin Biotech Lexaria Bioscience Relmada Therapeutics (NASDAQ:RLMD) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings. Which has better earnings and valuation, RLMD or SNOA? Sonoma Pharmaceuticals has higher revenue and earnings than Relmada Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$79.98M-$2.51-0.24Sonoma Pharmaceuticals$14.29M0.34-$3.46M-$3.10-0.96 Does the media favor RLMD or SNOA? In the previous week, Relmada Therapeutics had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Relmada Therapeutics and 0 mentions for Sonoma Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score. Company Overall Sentiment Relmada Therapeutics Neutral Sonoma Pharmaceuticals Neutral Is RLMD or SNOA more profitable? Relmada Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -24.23%. Sonoma Pharmaceuticals' return on equity of -58.73% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -181.26% -151.23% Sonoma Pharmaceuticals -24.23%-58.73%-21.05% Do analysts recommend RLMD or SNOA? Relmada Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 746.88%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Sonoma Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in RLMD or SNOA? 45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 20.7% of Relmada Therapeutics shares are held by company insiders. Comparatively, 3.9% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, RLMD or SNOA? Relmada Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. SummaryRelmada Therapeutics beats Sonoma Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.90M$2.49B$5.48B$9.54BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-0.968.9728.8623.83Price / Sales0.34433.83371.4566.14Price / CashN/A157.7635.4557.96Price / Book1.104.838.265.54Net Income-$3.46M$31.62M$3.25B$259.28M7 Day Performance-12.57%-5.28%-3.75%-4.67%1 Month Performance2.40%4.38%4.27%4.37%1 Year Performance831.46%-2.49%25.85%17.91% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma PharmaceuticalsN/A$2.99+0.3%N/A+745.1%$4.90M$14.29M-0.96180Upcoming EarningsGap DownRLMDRelmada Therapeutics4.4542 of 5 stars$0.64+0.2%$5.00+678.8%-84.0%$21.31MN/A-0.2610News CoverageUpcoming EarningsPASGPassage Bio3.3768 of 5 stars$6.82-3.3%$150.00+2,101.0%-69.8%$21.15MN/A-0.33130Gap DownCASICASI Pharmaceuticals3.9515 of 5 stars$1.71+5.2%$4.00+134.6%-81.7%$20.97M$28.54M-0.67180Positive NewsGap UpCMMBChemomab Therapeutics2.9438 of 5 stars$1.10+0.8%$8.50+673.4%-11.6%$20.73MN/A-1.4520FNCHFinch Therapeutics GroupN/A$12.50-0.4%N/A+556.3%$20.08MN/A-1.42190RLYBRallybio1.955 of 5 stars$0.48-5.7%$10.00+2,005.3%-59.5%$19.77M$640K-0.4440Negative NewsShort Interest ↑SYBXSynlogic1.0264 of 5 stars$1.62-0.3%N/A-14.0%$18.90M$10K-0.6480Upcoming EarningsLPCNLipocine2.6212 of 5 stars$3.36-1.2%$9.00+167.9%-38.0%$17.97M$11.20M-3.2910Positive NewsUpcoming EarningsMBRXMoleculin Biotech2.6941 of 5 stars$0.60+8.7%$4.00+568.9%-70.7%$17.95MN/A0.0020News CoverageUpcoming EarningsShort Interest ↑Gap DownLEXXLexaria Bioscience2.6961 of 5 stars$0.90+1.0%$4.00+342.5%-78.6%$17.68M$615.92K-1.357News CoverageAnalyst ForecastAnalyst RevisionGap Down Related Companies and Tools Related Companies Relmada Therapeutics Competitors Passage Bio Competitors CASI Pharmaceuticals Competitors Chemomab Therapeutics Competitors Finch Therapeutics Group Competitors Rallybio Competitors Synlogic Competitors Lipocine Competitors Moleculin Biotech Competitors Lexaria Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
